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Vitamin C supplementation is generally regarded as benign. )ere has been a resurgence of interest in the general medical
community regarding the use of vitamin C most notably in the care of sepsis. Nonetheless, caution must be taken if supra-
physiologic vitamin C supplementation is being administered as it should be considered a medication just like any other. We
present a case of hemolysis in a glucose-6-phosphate dehydrogenase- (G6PD-) de9cient patient receiving high-dose vitamin C
infusions for his rheumatoid arthritis.
1. Introduction
Vitamin C is a water-soluble vitamin that is generally
regarded as a benign medical intervention if supplemented.
)ough the bene9ts of vitamin C have been extolled for
many years, there has been a resurgence of interest in the
general medical community regarding the use of vitamin C
most notably in the care of sepsis. For most patients, sup-
plementing with vitamin C is benign. However, there
remain patient populations for which caution must be used
if vitamin C supplementation is being administered at levels
that are considered supraphysiologic. We present a case of
hemolysis in a glucose-6-phosphate dehydrogenase- (G6PD-)
de9cient patient receiving vitamin C infusions for his
rheumatoid arthritis.
2. Case Presentation
A 59-year-old African American male with a past medical
history of chronic lymphocytic leukemia (CLL)/small lym-
phocytic lymphoma (SLL), hypertension, and rheumatoid
arthritis presented from an outside facility with symptomatic
anemia and white blood cell elevation that was noted to be
predominately lymphocytic. He had a known history of
CLL/SLL via lymph node biopsy that was diagnosed three
months prior to admission. At the outside facility, he was
noted to be hypoxic and required four liters of oxygen/minute
to maintain oxygen saturation above 85%. An arterial blood
gas (ABG) was performed demonstrating a pH of 7.53, pCO2
of 32mmHg, and a PaO2 of 550mmHg while on 4 L/min of
oxygen. Methemoglobin and carboxyhemoglobin levels were
automatically drawn as part of the ABG assay. )is revealed
a methemoglobinemia of 5.9% and a carboxyhemoglobin
elevation of 4%. Other labs demonstrated a hemoglobin level
of 5.9 g/dL with an elevation of his white blood cell count to
53.10 k/uL. He was also noted to have an elevated lactate
dehydrogenase and reduced haptoglobin level concerning
for intravascular hemolysis. Due to his history of CLL/SLL,
there was a concern that his anemia was due to CLL marrow
in9ltration or an autoimmune hemolytic anemia. )e patient
was subsequently transferred to our facility for further
management.
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Upon interview, he endorsed three days of shortness of
breath with associated weakness and dizziness prior to
admission to the outside facility. He also noted that he
had some associated back pain with very dark urine. In light
of his elevated carboxyhemoglobin and methemoglobin
levels, we asked him social and exposure questions. He
denied smoking, recent exposure to exhaust or 9re, local
anesthetics, and topical or oral numbing medications. In-
terestingly, he noted that he had a very similar episode four
months prior after receiving an IV dose of vitamin C for
his rheumatoid arthritis that had been uncontrolled with
biologics. At that time, he received a single dose of packed
red blood cells and demonstrated clinical improvement. He
was discharged home after stabilization of his hemoglobin.
He stated that, prior to this most recent episode, he had
received 75 grams of intravenous high-dose vitamin C. He
noted that, within an hour of the infusion, he started to
develop shortness of breath.
Upon arrival to our facility, the patient was started on
high-dose prednisone as the concern was that his CLL/SLL
could have caused the hemolysis. While his lymphocytosis
did decrease on the steroids, dropping from 53.1 k/uL to
33.3 k/uL, he continued to have hemolysis. He developed
acute kidney injury thought to be secondary to hemolysis that
resolved with Guid administration. His course was rather
uncomplicated with a total of three units of packed red blood
cells transfused through a 9ve-day inpatient stay to com-
pensate for his continued hemolysis even in the setting of
improved lymphocytosis. His hemoglobin eventually stabi-
lized, and he was discharged home. A G6PD screen was
performed during his stay, and this was negative for de-
9ciency. As there was a strong suspicion of a G6PD de9ciency
due to the onset of hemolysis and symptoms after high-dose
vitamin C infusion with resultant methemoglobinemia, we
requested records from the physician who administered the
high-dose vitamin C. )ese records revealed that two G6PD
assays prior had demonstrated low G6PD levels.
3. Discussion
Pharmacologically dosed vitamin C has been used for
chronic illnesses including hypertension, cancer, arthritis,
Parkinson’s disease, and innumerable other diseases for the
past forty years [1]. )e perceived bene9ts of this in-
tervention outweigh the perceived risks as vitamin C is
generally considered a benign intervention in most clini-
cians’ minds. Nonetheless, caution needs to be exercised
with high-dose vitamin C in patients with G6PD de9ciency.
G6PD de9ciency is a hereditary X-linked recessive
disorder with an estimated worldwide prevalence of at least
329 million people. Prevalence varies among diLerent
geographical regions and ethnicities. Because of the X-linked
nature of this disorder and subsequent X-chromosomal
inactivation of females, the clinical phenotype is relatively
variable. As a result, most prevalence studies are estimated
based on male subjects as the phenotypic presentation is
more stable [2]. When broken down by race, African
Americans (10.2%) and Asians (3.6%) were more likely to
have G6PD de9ciency than Hispanics or Caucasians [3].
)ere are over a hundred identi9ed mutations of the
G6PD gene, resulting in diLering phenotypes with variable
amounts of enzyme de9ciency. )e majority of patients with
G6PD de9ciency remain asymptomatic throughout their
lives. Males are disproportionately aLected when serious
clinical consequences occur because of the X-linked nature
of the disease. When the disease becomes clinically apparent,
the two most common manifestations are neonatal jaundice
and hemolytic anemia after exposure to oxidizing medica-
tions or infections [2].
G6PD catalyzes the 9rst step of the pentose phosphate
pathway, one function of which is to protect cells against
oxidative damage [2, 4]. By reducing nicotinamide adenine
dinucleotide phosphate (NADP) to nicotinamide adenine
dinucleotide phosphate hydrogen (NADPH), G6PD allows
the cells to maintain glutathione in its reduced form. )is in
turn allows glutathione peroxidase to function properly and
rid the cells of peroxide [4]. Erythrocytes rely exclusively on
the pentose phosphate pathway and therefore G6PD to
provide NADPH for this purpose since they lack mito-
chondria [2]. )e rate of G6PD activity is controlled by the
concentrations of NADPH and NADP in the cell. When
NADPH is oxidized to NADP, G6PD activity increases to
replenish NADPH [4]. In G6PD de9ciency, erythrocytes are
limited in their ability to increase G6PD activity and are,
therefore, more vulnerable to oxidative damage [2]. )ough
there can be an element of extravascular hemolysis in G6PD
de9ciency with the formation of Heinz bodies from dena-
tured hemoglobin passing through the reticuloendothelial
system [3], the primary hemolysis in G6PD de9ciency is
intravascular and accounts for the increased LDH and de-
creased haptoglobin seen in the patient [5].
In this case, the patient’s ABG was helpful in diagnosis
and was the lab abnormality that prompted the team to
suspect G6PD de9ciency as the underlying cause of he-
molysis. Carboxyhemoglobin is often caused by various
exposures but can also be caused by increased endogenous
production of carbon monoxide. Among the major causes of
increased endogenous production is that of increased heme
catabolism. In most cases of hemolysis, increased levels of
carboxyhemoglobin are to be expected and can correlate
with the degree of hemolysis [6]. In addition to the increase
in carboxyhemoglobin, our patient also had elevated met-
hemoglobin. Elevated methemoglobin levels, similar to
carboxyhemoglobin, can be caused by various exposures and
are usually caused by exposure rather than hereditary
methemoglobinemia. Methemoglobin rises when heme is
oxidized to the ferric form (Fe3+) from the normal ferrous
(Fe2+) [7]. In G6PD de9ciency, the inability to protect
against oxidative damage can lead to methemoglobinemia.
)e enzyme that reduces methemoglobin, NADH-
cytochrome b5 reductase, normally keeps this value at less
than 1%, but in cases of acute oxidative stress, this can be
overwhelmed as was seen with the patient’s increased
methemoglobin level [8].
)e gold standard for diagnosis of G6PD de9ciency is
mainly the one performed by biochemical quantitative
analysis using spectrophotometry [9]. Rapid screening spot
tests have allowed easier and faster access to determine
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G6PD status [2]. More speci9cally, when viewed under
ultraviolet lighting, the lack of Guorescence of NADPH
being generated from NADP in the pentose-phosphate
pathway provides a positive 9nding qualitatively [2, 10, 11].
If suspected, however, one must avoid the rapid Guorescent
spot test during times of acute hemolysis as the qualitative
screen can give a false-negative interpretation [12]. )e
process of hemolytic anemia causes degradation of aged
erythrocytes with lower levels of G6PD. )e resultant re-
active reticulocytosis that occurs during this hemolysis
creates new erythrocytes that have normal levels of G6PD
initially [13]. In our case, the G6PD screen during his
admission while acutely hemolyzing was normal. Our
clinical suspicion was great enough based on history, and
his underlying methemoglobinemia that inquiry into the
patient’s medical records from his various outside providers
was made con9rming two G6PD enzyme assays below
normal limits.
Various etiologies can provoke an acute hemolytic ep-
isode in patients with G6PD de9ciency. )e end result is
oxidative stress within the red blood cells. Most documented
causes of hemolysis are either from food or medication
ingestion. Common medications that are cited include
dapsone, methylene blue, nitrofurantoin, primaquine, ras-
buricase, and NSAIDs [14]. Classic food items include fava
beans and other legumes, red wine (sul9tes), tonic water
(quinine), vitamin K, and menthol. It is diOcult to identify
many drug interactions that may lead to hemolysis from in
vitro studies, as metabolic byproducts can lead to hemolysis.
Additionally, the high variability of G6PD de9ciency,
particularly in females due to X-chromosomal inactivation,
can present with variable amounts of hemolysis [15]. Other
documented causes of hemolysis in G6PD-de9cient in-
dividuals include infections [16], DKA [17], and hypogly-
cemia [18].
Ascorbic acid is well known as an antioxidant as it is able
to donate an electron to reduce oxidizing radicals and may be
protective in G6PD de9ciency at slightly supraphysiologic
levels [19]. )ough high doses of vitamin C have been shown
to cause little sequela in healthy patients [20], case reports
have documented high doses of vitamin C causing hemolysis
in G6PD-de9cient patients [1, 21, 22]. Studies have shown that
high doses of ascorbic acid decrease the function and survival
of G6PD-de9cient red blood cells as well [23]. High-dose
ascorbic acid is thought to promote the production of hy-
drogen peroxide as a by-product of its cycling between its
ionized form and the ascorbate radical form [24]. Hydrogen
peroxide is a potent oxidizer, and increased production results
in damage of G6PD-de9cient RBCs and ultimately hemolysis
in these patients. )e enzyme glutathione peroxidase needs
reduced glutathione to help eliminate hydrogen peroxide. As
mentioned, the decrease in NADPH decreases the overall
storage of reduced glutathione and essentially renders the
glutathione peroxidase ineLective [4]. Our patient’s imme-
diate symptoms after both doses of vitamin C infusion im-
plicated vitamin C-associated hemolysis in light of his low
level of G6PD that had been measured in the past.
In a recent retrospective before and after study by Marik
et al., early treatment with high-dose intravenous vitamin C
combined with corticosteroids and thiamine showed prom-
ising results, leading to reduced end-organ damage and
mortality in severe sepsis and septic shock with reduced ICU
length of stay [25]. While further investigation is required for
validation, such a treatment protocol has the potential to be
widely adopted based on how benign the underlying in-
terventions are perceived. Care must be exercised in certain
groups, as the resultant hemolysis from high-dose vitamin C
could be misconstrued as worsening sepsis rather than an
iatrogenic insult in a G6PD patient. )is could lead to
continuing a therapy that could be potentially fatal in a select
group of patients.
4. Conclusion
Our case showed that G6PD de9ciency should be con-
sidered any time hemolytic anemia ensues after a medi-
cation is administered. Additionally, our case highlighted
that an acute hemolytic anemia associated with methe-
moglobinemia by no means diagnostic could lead the
clinician to a potential diagnosis of G6PD de9ciency with
large amounts of hemolysis. Finally, our case exempli9ed
the importance of understanding the limitation of quali-
tative testing in an acute hemolytic reaction. )ough
supraphysiologic vitamin C is considered benign in most
people, it can be associated with major morbidity and even
mortality in G6PD-de9cient patients. Care must be taken to
remember that, when administered at high doses, vitamin
C is a medication with side eLects just like any other
medication one would prescribe. For the clinician who will
be utilizing vitamin C at supraphysiologic doses, screening
should be considered prior to utilization, particularly in
ethnicities with a higher prevalence, to avoid potential false
negatives during treatment and, more importantly, iatro-
genic harm to the patient.
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